InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,705.45
(
-1.86%
)
US TECH 100
19,442.40
(
0.46%
)
Dow Jones
41,763.46
(
-0.90%
)
Brent Oil
74.61
(
0.80%
)
Bitcoin
69,290.99
(
-1.31%
)
Post# of 253503
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120650
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: turtlepower post# 96401

Wednesday, 05/26/2010 7:34:53 AM

Wednesday, May 26, 2010 7:34:53 AM

Post# of 253503
Yes, MRK will presumably have access to the blinded anemia data from the SPRINT-2 and RESPOND-2 trials in addition to the open-label data from the anemia trial. All told, this should allow MRK to make an informed judgment about when to submit the Boceprevir NDA.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up